Investigating how immune checkpoint inhibitors affect autoimmune responses
Immune Checkpoint Inhibition and humoral immune response in systemic autoimmunity
This study is looking at how a specific part of the immune system, called the PD-1 receptor, affects autoimmune diseases like inflammatory arthritis, and it aims to find out how treatments that block this receptor might lead to these conditions, so we can improve care for patients dealing with these issues.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-10898002 on NIH RePORTER |
What this research studies
This research explores the role of the PD-1 immune checkpoint receptor in regulating systemic autoimmunity and humoral immunity. It aims to understand how immune checkpoint inhibitors, like anti-PD-1, can lead to inflammatory arthritis and other autoimmune conditions. Using innovative humanized mouse models, the study will analyze the mechanisms by which these biologics influence immune responses and compare clinical data from patients experiencing immune-related adverse events with those suffering from rheumatoid arthritis. The goal is to uncover the underlying similarities and differences that could inform better treatment strategies.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients receiving immune checkpoint inhibitors who are experiencing or at risk for autoimmune reactions.
Not a fit: Patients without autoimmune conditions or those not undergoing treatment with immune checkpoint inhibitors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved understanding and management of autoimmune responses triggered by cancer treatments, potentially enhancing patient care.
How similar studies have performed: Previous research has shown promising results in understanding immune checkpoint inhibitors' effects on autoimmune conditions, but this specific approach using humanized models is relatively novel.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Zeng, Hu — Mayo Clinic Rochester
- Study coordinator: Zeng, Hu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.